| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 30th June 2020 | Beth Hecht | 3,731 | Grant/award etc. | $2.26 | $8,432.06 |
| 10th June 2020 | Alan L Heller | 23,453 | Grant/award etc. | $0.00 | |
| 10th June 2020 | John P. Schmid | 23,453 | Grant/award etc. | $0.00 | |
| 10th June 2020 | Gregory J Robitaille | 23,453 | Grant/award etc. | $0.00 | |
| 10th June 2020 | Beth Hecht | 23,453 | Grant/award etc. | $0.00 | |
| 10th June 2020 | Linda M Szyper | 23,453 | Grant/award etc. | $0.00 | |
| 10th June 2020 | Bryant Fong | 23,453 | Grant/award etc. | $0.00 | |
| 10th June 2020 | James A. Jr. Robinson | 23,453 | Grant/award etc. | $0.00 | |
| 13th March 2020 | Beth Hecht | 4,000 | Open or private purchase | $1.97 | $7,880.00 |
| 2nd March 2020 | Gerald W. Mc Laughlin | 290,000 | Grant/award etc. | $0.00 |
Neos Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products. The firm manufactures and markets its generic version of the branded product Tussionex. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.
Ticker: NEOS
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1467652
Employees: 213
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $13 M (-24%)
Inventory, Net: $9 M (0%)
Assets, Current: $40 M (-39%)
Property, Plant and Equipment, Net: $7 M (-9%)
Other Assets, Noncurrent: $1 M (-17%)
Assets: $63 M (-31%)
Accounts Payable, Current: $9 M (42%)
Accrued Liabilities, Current: $26 M (0%)
Liabilities, Current: $61 M (-3%)
Other Liabilities, Noncurrent: $154 Th (-3%)
Common Stock, Value, Issued: $50 Th (0%)
Common Stock, Shares, Issued: $50 M (0%)
Retained Earnings (Accumulated Deficit): $347 M (0%)
Stockholders' Equity (Parent): $16 M (0%)
Liabilities and Equity: $63 M (-31%)
Revenue: $13 M (0%)
Cost of Revenue: $6 M (-52%)
Gross Margin: $7 M (-52%)
Research and Development: $1 M (-60%)
Sales and Marketing: $5 M (-59%)
General and Administrative Expenses: $4 M (-54%)
Operating Income/Loss: $3 M (-67%)
